Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus

W. Stohl, S. Metyas, S. M. Tan, Gurtej S. Cheema, B. Oamar, V. Roschke, K. Wu, K. P. Baker, D. M. Hilbert

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

Objective: To assess longitudinal expression of a proliferation-inducing ligand (APRIL) in patients with systemic lupus erythematosus (SLE) and its correlation with B lymphocyte stimulator (BLyS) expression, serum anti-dsDNA titres, and clinical disease activity. Methods: Sixty eight patients with SLE were longitudinally followed up for a median of 369 days. At each visit the physician assessed disease activity by SLEDAI, and blood was collected for determination of serum APRIL and BLyS levels and of blood APRIL and BLyS mRNA levels. Fifteen normal control subjects underwent similar laboratory evaluation. Results: Dysregulation of APRIL was not as great as that of BLyS. Changes in serum levels of APRIL and BLyS over time were usually discordant, whereas blood levels of APRIL and BLyS mRNA strongly paralleled each other. Serum APRIL levels modestly, but significantly, inversely correlated with serum anti-dsDNA titres in anti-dsDNA positive patients analysed in aggregate. Moreover, serum APRIL levels modestly, but significantly, inversely correlated with clinical disease activity in all patients analysed in aggregate. Conclusion: Serum levels of APRIL and BLyS are differentially regulated. APRIL may serve as a down modulator of serological and/or clinical autoimmunity in patients with SLE. This may have important ramifications for BLyS targeted treatment, and it remains to be determined whether agents which neutralise only BLyS will be preferable to agents which neutralise both BLyS and APRIL.

Original languageEnglish (US)
Pages (from-to)1096-1103
Number of pages8
JournalAnnals of the Rheumatic Diseases
Volume63
Issue number9
DOIs
StatePublished - Sep 2004
Externally publishedYes

Fingerprint

B-Cell Activating Factor
Systemic Lupus Erythematosus
Ligands
Serum
Blood
Messenger RNA
Autoimmunity
Modulators

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus. / Stohl, W.; Metyas, S.; Tan, S. M.; Cheema, Gurtej S.; Oamar, B.; Roschke, V.; Wu, K.; Baker, K. P.; Hilbert, D. M.

In: Annals of the Rheumatic Diseases, Vol. 63, No. 9, 09.2004, p. 1096-1103.

Research output: Contribution to journalArticle

Stohl, W. ; Metyas, S. ; Tan, S. M. ; Cheema, Gurtej S. ; Oamar, B. ; Roschke, V. ; Wu, K. ; Baker, K. P. ; Hilbert, D. M. / Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus. In: Annals of the Rheumatic Diseases. 2004 ; Vol. 63, No. 9. pp. 1096-1103.
@article{6fead29296354ba398bf6d0a7980a49d,
title = "Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus",
abstract = "Objective: To assess longitudinal expression of a proliferation-inducing ligand (APRIL) in patients with systemic lupus erythematosus (SLE) and its correlation with B lymphocyte stimulator (BLyS) expression, serum anti-dsDNA titres, and clinical disease activity. Methods: Sixty eight patients with SLE were longitudinally followed up for a median of 369 days. At each visit the physician assessed disease activity by SLEDAI, and blood was collected for determination of serum APRIL and BLyS levels and of blood APRIL and BLyS mRNA levels. Fifteen normal control subjects underwent similar laboratory evaluation. Results: Dysregulation of APRIL was not as great as that of BLyS. Changes in serum levels of APRIL and BLyS over time were usually discordant, whereas blood levels of APRIL and BLyS mRNA strongly paralleled each other. Serum APRIL levels modestly, but significantly, inversely correlated with serum anti-dsDNA titres in anti-dsDNA positive patients analysed in aggregate. Moreover, serum APRIL levels modestly, but significantly, inversely correlated with clinical disease activity in all patients analysed in aggregate. Conclusion: Serum levels of APRIL and BLyS are differentially regulated. APRIL may serve as a down modulator of serological and/or clinical autoimmunity in patients with SLE. This may have important ramifications for BLyS targeted treatment, and it remains to be determined whether agents which neutralise only BLyS will be preferable to agents which neutralise both BLyS and APRIL.",
author = "W. Stohl and S. Metyas and Tan, {S. M.} and Cheema, {Gurtej S.} and B. Oamar and V. Roschke and K. Wu and Baker, {K. P.} and Hilbert, {D. M.}",
year = "2004",
month = "9",
doi = "10.1136/ard.2003.018663",
language = "English (US)",
volume = "63",
pages = "1096--1103",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "9",

}

TY - JOUR

T1 - Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus

AU - Stohl, W.

AU - Metyas, S.

AU - Tan, S. M.

AU - Cheema, Gurtej S.

AU - Oamar, B.

AU - Roschke, V.

AU - Wu, K.

AU - Baker, K. P.

AU - Hilbert, D. M.

PY - 2004/9

Y1 - 2004/9

N2 - Objective: To assess longitudinal expression of a proliferation-inducing ligand (APRIL) in patients with systemic lupus erythematosus (SLE) and its correlation with B lymphocyte stimulator (BLyS) expression, serum anti-dsDNA titres, and clinical disease activity. Methods: Sixty eight patients with SLE were longitudinally followed up for a median of 369 days. At each visit the physician assessed disease activity by SLEDAI, and blood was collected for determination of serum APRIL and BLyS levels and of blood APRIL and BLyS mRNA levels. Fifteen normal control subjects underwent similar laboratory evaluation. Results: Dysregulation of APRIL was not as great as that of BLyS. Changes in serum levels of APRIL and BLyS over time were usually discordant, whereas blood levels of APRIL and BLyS mRNA strongly paralleled each other. Serum APRIL levels modestly, but significantly, inversely correlated with serum anti-dsDNA titres in anti-dsDNA positive patients analysed in aggregate. Moreover, serum APRIL levels modestly, but significantly, inversely correlated with clinical disease activity in all patients analysed in aggregate. Conclusion: Serum levels of APRIL and BLyS are differentially regulated. APRIL may serve as a down modulator of serological and/or clinical autoimmunity in patients with SLE. This may have important ramifications for BLyS targeted treatment, and it remains to be determined whether agents which neutralise only BLyS will be preferable to agents which neutralise both BLyS and APRIL.

AB - Objective: To assess longitudinal expression of a proliferation-inducing ligand (APRIL) in patients with systemic lupus erythematosus (SLE) and its correlation with B lymphocyte stimulator (BLyS) expression, serum anti-dsDNA titres, and clinical disease activity. Methods: Sixty eight patients with SLE were longitudinally followed up for a median of 369 days. At each visit the physician assessed disease activity by SLEDAI, and blood was collected for determination of serum APRIL and BLyS levels and of blood APRIL and BLyS mRNA levels. Fifteen normal control subjects underwent similar laboratory evaluation. Results: Dysregulation of APRIL was not as great as that of BLyS. Changes in serum levels of APRIL and BLyS over time were usually discordant, whereas blood levels of APRIL and BLyS mRNA strongly paralleled each other. Serum APRIL levels modestly, but significantly, inversely correlated with serum anti-dsDNA titres in anti-dsDNA positive patients analysed in aggregate. Moreover, serum APRIL levels modestly, but significantly, inversely correlated with clinical disease activity in all patients analysed in aggregate. Conclusion: Serum levels of APRIL and BLyS are differentially regulated. APRIL may serve as a down modulator of serological and/or clinical autoimmunity in patients with SLE. This may have important ramifications for BLyS targeted treatment, and it remains to be determined whether agents which neutralise only BLyS will be preferable to agents which neutralise both BLyS and APRIL.

UR - http://www.scopus.com/inward/record.url?scp=2942750585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942750585&partnerID=8YFLogxK

U2 - 10.1136/ard.2003.018663

DO - 10.1136/ard.2003.018663

M3 - Article

C2 - 15308519

AN - SCOPUS:2942750585

VL - 63

SP - 1096

EP - 1103

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 9

ER -